Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results [Accessibility Statement] Skip Navigation- Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)- Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025- Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025- Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/Bi ...